Research Article
Prolonged ICU Stay in Severe and Critically-Ill COVID-19 Patients Who Received Convalescent Plasma Therapy
Table 1
Baseline characteristics of both groups.
| | Characteristics | Control n = 131 | Plasma n = 48 | |
| | Gender-n (%) | | | | | Male | 88 (67.2) | 36 (75) | 0.32 | | Female | 43 (32.8) | 12 (25) | |
| | Age | | | | | Mean (SD) | 51.2 (11.6) | 49.5 (11.4) | 0.36 |
| | Age group-n (%) | | | | | < 45 years | 35 (26.7) | 16 (33.3) | 0.39 | | > 45 years | 96 (73.3) | 32 (66.7) | |
| | Status-n (%) | | | | | Confirmed infection | 106 (80.9) | 37 (77.1) | 0.57 | | Suspected infection | 25 (19.1) | 11 (22.9) | |
| | Healthcare worker-n (%) | | | | | Yes | 61 (46.6) | 23 (47.9) | 0.87 | | No | 70 (53.4) | 25 (52.1) | |
| | Duration from onset of symptoms to ICU admission-days | | | | | Median (IQR) | 8 (6) | 8 (3) | 0.43 |
| | Known contact with confirmed-case-n (%) | | | | | Yes | 17 (13) | 12 (25) | 0.06 | | No | 114 (87) | 36 (75) | |
| | Known comorbidities | | | |
| | Hypertension-n (%) | | | | | Yes | 43 (32.8) | 15 (31.3) | 0.84 | | No | 88 (67.2) | 33 (68.8) | |
| | Diabetes mellitus-n (%) | | | | | Yes | 61 (46.6) | 15 (31.3) | 0.07 | | No | 70 (53.4) | 33 (68.8) | |
| | Obesity-n (%) | | | | | Yes | 18 (13.7) | 7 (14.6) | 0.89 | | No | 113 (86.3) | 41 (85.4) | |
| | Initial symptoms | | | |
| | Fever-n (%) | | | | | Yes | 69 (52.7) | 30 (62.5) | 0.67 | | No | 62 (47.3) | 18 (37.5) | |
| | Mild respiratory symptoms-n (%) | | | | | Yes | 72 (55) | 29 (60.4) | 0.51 | | No | 59 (45) | 19 (39.6) | |
| | Shortness of breath-n (%) | | | | | Yes | 35 (26.7) | 13 (27.1) | 0.96 | | No | 96 (73.3) | 35 (72.9) | |
| | Gastrointestinal symptoms-n (%) | | | | | Yes | 16 (12.2) | 2 (4.2) | 0.13 | | No | 115 (87.8) | 46 (95.8) | |
| | Mechanical ventilation | | | |
| | Mechanical ventilation on admission-n (%) | | | | | Yes | 68 (51.9) | 11 (22.9) | <0.01 | | No | 63 (48.1) | 37 (78.1) | |
| | Mechanical ventilation during ICU stay-n (%) | | | | | Yes | 84 (64.11) | 29 (60.4) | 0.65 | | No | 47 (35.9) | 19 (39.6) | |
| | Laboratory findings | | | |
| | White blood cells count (×109/L) | | | | | Mean (SD) | 12.6 (6) | 9.12 (4.3) | <0.001 |
| | Neutrophil-Lymphocyte ratio | | | | | Median (IQR) | 11.2 (12.25) | 9.2 (10.8) | 0.21 |
| | PaO2/FiO2 Ratio | | | | | Median (IQR) | 110 (114,9) | 117.4 (68.3) | 0.95 |
| | D-dimer (ng/mL) | | | | | Median (IQR) | 2,130 (7,730)1 | 1,100 (1,747.5) | <0.001 |
| | Creatinine serum (mg/dL) | | | | | Median (IQR) | 1.0 (0.6) | 0.9 (0.4) | 0.03 |
| | Random blood glucose (mg/dL) | | | | | Median (IQR) | 177 (113) | 145.5 (128.5) | 0.41 |
| | Outcome measures | | | |
| | Mortality-n (%) | | | | | Deceased | 76 (58) | 23 (47.9) | 0.23 | | Discharged to low-care | 55 (42) | 25 (52.1) | |
| | Length of stay | | | | | Mean (SD) | 7.74 (5.02) | 11.27 (4.97) | <0.001 |
| | Length of stay-n (%) | | | | | <7 days | 68 (51.9) | 7 (14.6) | <0.001 | | >7 days | 63 (48.1) | 41 (85.4) | |
| | Improvement of oxygen support device-n (%) | | | | | Yes | 40 (30.5) | 20 (41.7) | 0.16 | | No | 91 (69.5) | 28 (58.3) | |
|
|
1Baseline D-dimer was measured in 48 (100%) patients in plasma group and 122 (93%) patients in control group.
|
